Single-Dose and Multiple-Dose, Dose-Escalation Study With LY2599666 to Evaluate the Safety, Pharmacokinetics, and Tolerability in Healthy Subjects and Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild-to-Moderate Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 12 Jan 2017
At a glance
- Drugs LY 2599666 (Primary) ; Solanezumab
- Indications Alzheimer's disease; Mild cognitive impairment
- Focus Adverse reactions
- Sponsors Eli Lilly
- 07 Jun 2017 Biomarkers information updated
- 06 Jan 2017 Status changed from active, no longer recruiting to discontinued.
- 05 Jan 2017 Status changed from recruiting to active, no longer recruiting.